Research Projects from Government Funding Agencies

Major Research Project

| Name of | Duratio | | Amount | Name of | | Year of |
|--------------|---------|--------------------------------------|-----------------|-------------|----------------------|----------|
| Principal | n of | Name of the research | / Fund | funding | Department of | Sanction |
| Investigator | project | project | received | agency | recipient | |
| Dr. S. N. | 03 | Development of some | 13.49 | UGC | Pharma | 2010 |
| Mokale | years | anti-inflammatory | lakh | | Chemistry | |
| | | agents using modern | | | | |
| | | drug design Tech. | | | | |
| Dr. J. N. | 03 | Synthesis and | 6.30 | UGC | Quality | 2011 |
| Sangshetti | years | Antifungal Activity | lakh | | Assurance | |
| | | of Some New | | | | |
| | | Quinoline Analogues | | | | |
| Dr. A. G. | 03 | Synthesis and | 9.05 | UGC | Pharma | 2011 |
| Nikalje | years | Anticonvulsant | lakh | | Chemistry | |
| | | activity of some | | | | |
| | | hybrid heterocycles | | | | |
| Dr. J. N. | 01 | Modernization of | 13.80 | MODRO | Quality | 2011 |
| Sangshetti | years | Pharmaceutical | lakh | BS/ | Assurance | |
| | | Chemistry | | AICTE | | |
| | | Laboratory | | | | |
| Dr. Zahid | 03 | Synthesis | 12.08 | UGC | Quality | 2012 |
| Zaheer | years | pharmacological | lakh | | Assurance | |
| | | screening of some | | | | |
| | | new substituted- | | | | |
| | | 1,2,4- oxadiazoles as | | | | |
| | | anti-inflammatory | | | | |
| D G M | 0.2 | agents | 27 221 1 | - | D1 | 2012 |
| Dr. S. N. | 03 | Development of | 25.22lak | Fast | Pharma | 2012 |
| Mokale | years | Selective Estrogen | h | Track | Chemistry | |
| | | Receptor Modulators | | Project | | |
| | | for Treatment of | | for Young | | |
| | | Breast Cancer: | | Scientist / | | |
| | | Design, Synthesis, In- | | DST | | |
| | | Vitro and In-Vivo | | | | |
| Dr. J. N. | 03 | Screening Design & synthesis | 25.52 | Fast | Ouglity | 2013 |
| | | of Novel Inhibitor of | 23.32 lakh | Track | Quality Assurance | 2013 |
| Sangshetti | years | | iakii | Project | Assurance | |
| | | Peptide Deformylase as Antibacterial | | for Young | | |
| | | Agent | | Scientist / | | |
| | | Agent | | DST | | |
| | | | 1 | וטע | | |

| Dr. H. D. Une | 01 year | Modernization of Pharmacology Laboratory | 8.0 lakh | MODRO BS/ AICTE | Pharmacology | 2013 |
|-------------------------|-------------|--|---------------|-----------------------|----------------------|------|
| Dr. Rana Zainuddin | 02 years | Nanosponges- Novel Drug carrier for enhancement of solubility &stability of Drug | 4.45 lakh | UGC | Quality Assurance | 2014 |
| Mr. Nikhil Sakale | 02 years | Chemomodulatory influence of medicinal herbs in chemically induced carcinoma | 3.50 lakh | UGC | Pharmacology | 2014 |
| Dr.Santosh Mokale | 03 years | Design and Development of Hybrid Inhibitor to synchronously act on four biochemically distinct target for suppression of tumor growth in a synergistic manner" | 36.6 Lakh | SERB EMEQ | Pharma Chemistry | 2017 |
| Dr. J. N. Sangshetti | 03 years | Design, Synthesis and Biological Evaluation of Some New Mur B, Mur C, Mur D,Mur E and Mur F Inhibitors as Antibacterial Agents" | 38.55 lakh | SERB EMR | Quality Assurance | 2018 |

| Dr.Santosh Mokale | 03 years | Targetting KRAS mutant with a Covalent G12C Specific Inhibitor: Design Synthesis and Anticancer Screening of KRASG12C inhibitor for KRAS Mutant Cancers. | 48.23. Lakh | SERB EMEQ | Pharma Chemistry | 2022 |
|-------------------------|-------------|---|----------------|-----------------------------------|----------------------|------|
| Dr. J. N. Sangshetti | 03 years | "Targeting the Quorum sensing through Sortase A and Biofilm Inhibition: Design, Synthesis, Sortase A and Biofilm Inhibitory Potential of some NewAntibacterials". | 45 lakh | SERB Core Research Grant | Quality Assurance | 2024 |

Minor Research Project

| Name of | | | | | Depart | Year of | Year of |
|------------|---------|----------------------|----------|------------|----------|----------|----------|
| Principal | Duratio | | Amount / | Name of | ment of | Sanction | completi |
| Investigat | n of | Name of the research | Fund | funding | recipien | | on |
| or | project | project | received | agency | t | | |
| | | Cross-linked | | | | | |
| | | polymers for | | | | | 2020 |
| | | dissolution | | | Quality | 2018 | |
| Dr Rana | | enhancement of BCS | | Dr B A M | Assura | | |
| Zainuddin | 1 year | class II Drug. | 25,000 | University | nce | | |

| Date | Name of | Client Organization | Title of Consultancy of | Amount |
|------------|---------------------|-------------------------|---------------------------|--------------|
| From-To | faculty (Chief | | project | received (in |
| | Consultant) | | | Rupees) |
| 25/08/2015 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Ex- Vivo Comparative | 62000 |
| to | | Taloja, New Mumbai | Permeation of Diclofenac | |
| 01/12/2015 | | | Gels | |
| 08/08/2016 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 70,000 |
| to | | Taloja, New Mumbai | Studies of Luliconazole | |
| 26/10/2016 | | | Creams | |
| Auguest- | Dr. S.R. Lahoti | Gebbs Health Care | Training Consultancy for | 3.25000 |
| 2016 | | Solutions | Medical Coders | |
| 08/08/2016 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 70,000 |
| to | | Taloja, New Mumbai | Studies of Luliconazole | |
| 26/10/2016 | | | Lotion Formulations | |
| 08/08/2016 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 70,000 |
| to | | Taloja, New Mumbai | Studies of Decapeptide | |
| 26/10/2016 | | | Solution Formulations | |
| 07/03/2017 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 70,000 |
| to | | Taloja, New Mumbai | Studies of Clindamycin | |
| 04/07/2017 | | | Lotion Formulations | |
| 07/03/2017 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 70,000 |
| to | | Taloja, New Mumbai | Studies of Clindamycin | |
| 04/07/2017 | | | Gel Formulations | |
| 07/03/2017 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Comparative Permeation | 40,000 |
| to | | Taloja, New Mumbai | Studies of Spironolactone | |
| 04/07/2017 | | | Cream Formulations | |
| 11/05/2017 | Dr. S.R. Lahoti | Gebbs Health Care | Training Consultancy for | 70,000 |
| То | | Solutions | Medical Coders | |
| 05/08/2017 | | | | |
| 26/04/2018 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Ex-vivo Comparative | 85,000 |
| to | | Taloja, New Mumbai | Permeation Study | |
| 08/06/2018 | | | between Muscodac gel | |
| | | | and Volini gel. | |
| 11/09/2018 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Ex-vivo Comparative | 170000/- |
| to | | Taloja, New Mumbai | Permeation Studyof four | |
| 04/01/2019 | | | Luliconazole Gel | |
| | | | Formulations | |
| 21/8/2019 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Ex- Vivo Comparative | 85000/- |
| to | | Taloja, New Mumbai | Permeation of Muscodac | |

| 21/01/2020 | | | Gel Volini Gel | |
|------------|-----------------|-------------------------|------------------------|---------|
| 31/5/2019 | Dr. S.R. Lahoti | Alkem Laboratories Ltd. | Ex- Vivo Permeation of | 65000/- |
| to | | Taloja, New Mumbai | Melbild lotion | |
| 30/08/2019 | | | | |
| 24/4/2018 | Dr. Furquan | Lupin Limited | Tablet Sugar Coating | 30000/- |
| to | Khan | | Trials | |
| 24/7/2018 | | | | |
| 19/10/2019 | Dr. Furquan | Lupin Limited | Tablet Sugar Coating | 30000/- |
| to | Khan | | Trials | |
| 18/01/2020 | | | | |